Pituitary deficiency
MONDO:001512797 clinical trials for this condition and its sub-types, 0 tagged with Pituitary deficiency itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pituitary deficiency
-
Non-acquired pituitary hormone deficiency 0 trials · 85 incl. sub-types
5 sub-types
- Congenital hypogonadotropic hypogonadism 0 trials · 83 incl. sub-types Sub-types →
- Non-acquired combined pituitary hormone deficiency 1 trial · 3 incl. sub-types Sub-types →
- Isolated thyroid-stimulating hormone deficiency 1 trial
- Pituitary stalk interruption syndrome 1 trial
- Short stature due to GHSR deficiency 0 trials
-
Central diabetes insipidus 5 trials · 12 incl. sub-types
2 sub-types
- Neurohypophyseal diabetes insipidus 9 trials
- Acquired central diabetes insipidus 0 trials
-
Acquired pituitary hormone deficiency 0 trials · 1 incl. sub-types
4 sub-types
- Pituitary apoplexy 1 trial
- Iatrogenic or traumatic pituitary deficiency 0 trials
- Late-onset isolated ACTH deficiency 0 trials
- Primary hypophysitis 0 trials Sub-types →
Most studied deeper sub-types
-
Daily pill may replace growth hormone shots for children
Disease control Not yet recruitingThis study evaluates the long-term safety of an oral medication called LUM-201 for children with growth hormone deficiency (GHD). Children who completed a prior 12-month trial can receive LUM-201 daily for up to 36 additional months. The goal is to see if the pill is safe and tol…
Phase 3 • Sponsor: Lumos Pharma • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New Long-Acting growth hormone shot could mean fewer needles for kids
Disease control Not yet recruitingThis study tests a new medicine called GenSci134, a long-acting growth hormone, in 128 children with growth hormone deficiency (GHD). The goal is to find the best dose and see if it is safe and helps children grow taller. In the first part, children get one shot of GenSci134; in …
Phase 1/2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for Prader-Willi: drug targets uncontrollable hunger
Symptom relief Not yet recruitingThis study tests an experimental drug called BMB-101 in 16 adults with Prader-Willi syndrome who struggle with severe, constant hunger. The trial is double-blind and placebo-controlled, meaning some participants get the drug and some get a dummy treatment, and neither they nor th…
Phase 2 • Sponsor: Bright Minds Biosciences Pty Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
300 belgian kids to help unlock growth Hormone's metabolic secrets
Knowledge-focused Not yet recruitingThis study will follow 300 Belgian children with growth hormone deficiency for three years to see how their bodies respond to daily or weekly growth hormone shots. Researchers will measure growth, weight, blood sugar, fats, and other health markers. The goal is to understand whic…
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC